Abstract
Introduction
Cystic fibrosis (CF) related liver disease (CFLD) manifests as a wide
spectrum of hepatobiliary disease and can progress to need liver
transplantation. Elexacaftor/tezacaftor/ivacaftor (elx/tez/iva) is a
cystic fibrosis transmembrane conductance regulator (CFTR )
modulator which has superior efficacy compared to previously approved
modulators. Use of elx/tez/iva, should be approached with caution in
individuals with CFLD or following liver transplantation due to possible
increases in LFTs and drug-drug interactions with several
immunosuppressant medications.